Human bone marrow-mesenchymal stem cell-derived exosomal microRNA-188 reduces bronchial smooth muscle cell proliferation in asthma through suppressing the JARID2/Wnt/β-catenin axis

Shan, Lishen; Liu, Si; Zhang, Qinzhen; Zhou, Qianlan; Shang, Yunxiao

doi:10.1080/15384101.2021.2020432

Cited by 16 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that bone marrow aspirate MSCs-derived exosomes have a negative impact on the proliferation of activated peripheral blood mononuclear cells, and isolated B and T lymphocyte [38]. Abnormal proliferation of transforming growth factor (TGF)-β1-stimulated bronchial smooth muscle cell was also reduced following MSC-derived exosomes treatment [39]. Additionally, in a rat ischemiareperfusion injury model, MSC-derived exosomes treatment was found to improve tubular epithelial cell proliferation [40].…”

Section: Macrophage Viability and Morphologymentioning

confidence: 99%

A tailored bioactive 3D porous poly(lactic-acid)-exosome scaffold with osteo-immunomodulatory and osteogenic differentiation properties

et al. 2022

View full text Add to dashboard Cite

Polylactic acid (PLA) is a versatile and biodegradable scaffold widely used in biomedical fields to repair tissue defects. Exosomes derived from mesenchymal stem cells (MSCs) are nano-sized extracellular vesicles, which play an important role in tissue engineering in recent years. The primary focus of this study was to develop a bioactive 3D PLA scaffold using exosome-based strategy to improve its osteogenic and immunoregulatory potential. We firstly successfully isolated MSC-derived exosomes (MSC-Exo). Morphological analysis revealed that MSC-Exo exhibits a typical cup-shaped morphology with high expression of exosomal marker CD63. MSC-Exo internalization into recipient cells were also investigated using flow cytometry and confocal laser scanning microscopy. Porous 3D PLA scaffold coated MSC-Exo were used for immunoregulatory and osteogenic testing. Exosomes released from 3D PLA scaffold were validated in RAW264.7 and hBMSCs. The cell proliferation and live/dead assay indicated high biocompatibility for PLA-Exo scaffold. Additionally, PLA-Exo scaffold could reduce the pro-inflammatory marker expression and reactive oxygen species (ROS) production, indicating potential immunoregulatory potential. It is also confirmed that PLA-Exo scaffold could potentiate osteogenic differentiation in the osteogenesis assay. In conclusion, our results demonstrate this bioactive 3D-printed PLA scaffolds with MSC-Exo modification holds immunoregulatory potential and favor osteogenic differentiation, thus having potential applications in bone tissue regeneration.

show abstract

Section: Macrophage Viability and Morphologymentioning

confidence: 99%

A tailored bioactive 3D porous poly(lactic-acid)-exosome scaffold with osteo-immunomodulatory and osteogenic differentiation properties

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Studies have shown that engineered adipose-derived MSC-exos carrying miR-301a-3p could target and promote STAT3 expression, reverse platelet-derived growth factor-BB (PDGF-BB)-induced airway smooth muscle cell proliferation and migration, induce airway smooth muscle cell apoptosis, and reduce the secretion of inflammatory factors [ 64 ]. Another study showed that engineered human bone marrow-derived MSCs carrying microRNA-188 could inhibit the JARID2/Wnt/β-catenin axis, thereby reducing inflammatory cell infiltration, mucus production, and collagen deposition in the lung tissue of asthmatic mice [ 65 ].…”

Section: Chronic Lung Diseasesmentioning

confidence: 99%

Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment

Zhai,

Cui,

Chen

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Chronic lung diseases include an array of conditions that impact airways and lung structures, leading to considerable societal burdens. Mesenchymal stem cells (MSCs) and their exosomes (MSC-exos) can be used for cell therapy and exhibit a diverse spectrum of anti-inflammatory, antifibrotic, and immunomodulatory properties. Engineered MSC-exos possesses enhanced capabilities for targeted drug delivery, resulting in more potent targeting effects. Through various engineering modifications, these exosomes can exert many biological effects, resulting in specific therapeutic outcomes for many diseases. Moreover, engineered stem cell exosomes may exhibit an increased capacity to traverse physiological barriers and infiltrate protected lesions, thereby exerting their therapeutic effects. These characteristics render them a promising therapeutic agent for chronic pulmonary diseases. This article discusses and reviews the strategies and mechanisms of engineered MSC-exos in the treatment of chronic respiratory diseases based on many studies to provide new solutions for these diseases.

show abstract

“…Human BM-MSC-derived exosomal miR-188 inhibits ASMC proliferation induced by TGF-β1 by inhibiting the JARID2/Wnt/β-catenin axis, thus reducing lung collagen deposition in asthmatic mice. JARID2 is an mRNA target for miR-188 that activates the Wnt/β-catenin signaling pathway 100 . Rat-BM-MSC-derived miR-221-3p suppresses the expression of fibroblast growth factor 2 and the phosphorylation of extracellular signal–regulated kinase 1/2 signaling, thereby inhibiting the proliferation, migration, and ECM deposition of ASMC and alleviating OVA-induced pathological changes in asthmatic mice 101 .…”

Section: Msc-based Therapy For Asthmamentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement

Huang

Zeng

et al. 2023

Cell Transplant

View full text Add to dashboard Cite

Asthma is a complex and heterogeneous disease characterized by chronic airway inflammation, airway hyperresponsiveness, and airway remodeling. Most asthmatic patients are well-established using standard treatment strategies and advanced biologicals. However, a small group of patients who do not respond to biological treatments or are not effectively controlled by available treatment strategies remain a clinical challenge. Therefore, new therapies are urgently needed for poorly controlled asthma. Mesenchymal stem/stromal cells (MSCs) have shown therapeutic potential in relieving airway inflammation and repairing impaired immune balance in preclinical trials owing to their immunomodulatory abilities. Noteworthy, MSCs exerted a therapeutic effect on steroid-resistant asthma with rare side effects in asthmatic models. Nevertheless, adverse factors such as limited obtained number, nutrient and oxygen deprivation in vitro, and cell senescence or apoptosis affected the survival rate and homing efficiency of MSCs, thus limiting the efficacy of MSCs in asthma. In this review, we elaborate on the roles and underlying mechanisms of MSCs in the treatment of asthma from the perspective of their source, immunogenicity, homing, differentiation, and immunomodulatory capacity and summarize strategies to improve their therapeutic effect.

show abstract

Human bone marrow-mesenchymal stem cell-derived exosomal microRNA-188 reduces bronchial smooth muscle cell proliferation in asthma through suppressing the JARID2/Wnt/β-catenin axis

Cited by 16 publications

References 43 publications

A tailored bioactive 3D porous poly(lactic-acid)-exosome scaffold with osteo-immunomodulatory and osteogenic differentiation properties

A tailored bioactive 3D porous poly(lactic-acid)-exosome scaffold with osteo-immunomodulatory and osteogenic differentiation properties

Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment

Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement

Contact Info

Product

Resources

About